A docking score function for estimating ligand-protein interactions: Application to acetylcholinesterase inhibition

Journal of Medicinal Chemistry

Volumn 47, Issue 22, 2004, Pages 5492-5500

  Guo, Jianxin ^b   Hurley, Margaret M ^b   Wright, Jeffery B ^c   Lushington, Gerald H ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b U S ARMY RESEARCH LABORATORY   (United States)

^c US Army Research Development and Engineering Command   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ARTICLE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MODEL; SCORING SYSTEM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; BINDING SITES; CHOLINESTERASE INHIBITORS; CRYSTALLOGRAPHY, X-RAY; HUMANS; INDANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PIPERIDINES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6044238257     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049695v     Document Type: Article

References (41)

1. Taylor, P.; Radic, Z. The cholinesterases: from genes to proteins. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 281-320.
2. Massoulie, J.; Pezzementi, L.; Bon, S.; Krejci, E.; Velette, F. M. Molecular and cellular biology of the cholinestereases. Prog. Neurobiol. 1993, 41, 31-39.
3. Crismon, M. L. Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother. 1994, 28, 744-751.
4. Barner, E. L.; Gray, S. L. Donepezil use in Alzheimer disease. Ann. Pharmacother. 1998, 32, p 70-77.
5. Sidell, F. R.; Borak, J. Chemical warfare agents: II. Nerve agents. Ann. Emerg. Med. 1992, 21, p 865-871.
6. Marrs, T. C. Organophosphate poisoning. Pharmacol. Ther. 1993, 58, 51-66.
7. Barril, X.; Orozco, M.; Luque, F. J. Towards improved acetylcholinesterase Inhibitors: A structural and computational approach. Mini-Rev. Med. Chem. 2001, 1, 255-266.
8. Rachinsky, T. L; Camp, S.; Li, Y.; Ekstrom, J.; Newton, M.; Taylor, P. Molecular cloning of mouse acetylcholinesterase: tissue distribution of alternatively spliced mRNA species. Neuron 1990, 5, 317-327.
9. Bourne, Y.; Taylor, P.; Radic, Z.; Marchot, P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J. 2003, 22, 1-12.
10. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of aetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253, 872-879.
11. Harel, M.; Quinn, D. M.; Nair, H. K.; Silman, I.; Sussman, J. L. The X-ray Structure of a Transition State Analog Complex Reveals the Molecular Origins of the Catalytic Power and Substrate Specificity of Acetylcholinesterase. J. Am. Chem. Soc. 1996, 118 (10), 2340-2346.
12. Kojima, J.; Nakajima, K.; Ochiai, M.; Nakayama, K. Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. Methods. Find. Exp Clin. Pharmacol. 1997, 19, 245-251.
13. Sippl, W.; Contreras, J.-M.; Parrot, I.; Rival, Y. M.; Wermuth, C. G. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J. Comput.-Aided Mol. Des. 2001, 15, 395-410.
14. Sippl, W. Development of biologically active compounds by combining 3D QSAR and structure-based design methods. J. Comput.-Aided Mol. Des. 2002, 16, 825-830.
15. Kua, J.; Zhang, Y.; Mccammon, J. A. Studying enzyme binding specificity in acetylcholinesterase using a combined molecular dynamics and multiple dockign approach. J. Am. Chem. Soc. 2002, 124, 8260-8267.
16. Bernard, P.; Kireev, D. B.; Chretien, J. R.; Fortier, P.-L.; Coppet, L. Automated docking of 82 N-benzylpiperidine derivatives to mouse acetylcholinesterase and comparative molecular field analysis with natural alignment. J. Comput.-Aided Mol. Des. 1999, 13, 355-371.
17. Cho, S. J.; Garsia, M. L. S.; Bier, J.; Tropsha, A. Strucutre-Based Alignment and Comparative Molecular Field Analysis of Acetylcholinesterase Inhibitors. J. Med. Chem. 1996, 39, 5064-5071.
18. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
19. Jones, G.; Willett, P.; Glen, R.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997, 267, 727-748.
20. Rarey M.; Kramer, B.; Lengauer, T.; Klebe, G. J. A fast flexible docking method using an imcremental constructuion algorithm. J. Mol. Biol. 1996, 261, 470-489.
21. Haq, Z.-U.; Wellenzohn, B.; Liedl, K. r.; Rode, B. M. Molecular docking studies of Natural Cholinesterase Inhibiting Steroidal Alkaloids from Sarcococca saligna. J. Med. Chem. 2003, 46, 4087-4090.
22. Kryger, G.; Harel, M.; Giles, K.; Toker, L.; Velan, B.; Lazar, A.; Kronman, C.; Barak, D.; Ariel, N.; Shafferman, A.; Silman, I.; Sussman, J. L. Structure of Recombinant Native and E202Q Mutant Human Acetylcholinesterase Complexed with the Snake-Venom Toxin Fasciculin-II. Acta Crystallogr., Sect. D 2000, 56, 1385-1394.
23. Kryger, G.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with E2020(Aricept): implications for the design of new anti-Alzheimer drugs. Struct. Fold Des. 1999, 7, 297-307.
24. Sybyl / Unity, version 6.9; Tripos Inc.: St. Louis, MO, 2002.
25. Molecular Operating Enviroment (MOE) 2002.03; Chemical Computing Group Inc., Montreal, Quebec, Canada, 2002.
26. Halgren, T. A. MMFF VI. MMFF94s Option for Energy Minimization Studies. J. Comput. Chem. 1999. 20, 720-729.
27. Palin, R.; Clark, J. K.; Cowley, P.; Muir, A. W.; Pow, E.; Presser, A. B.; Taylor, R.; Zhang, M.-Q. Novel Piperidinium and Pyridinium Agents as Water-Soluble Acetylcholinesterase Inhibitors for the Reversal of Neutomuscular Blockade. Bioorg. Med. Chem. Lett. 2002, 12, 2569-2572.
28. Villalobos, A; Blake, J. F.; Biggers, C. K.; Butler, T. W.; Chapin, D. S.; Chen, Y. L.; Ives, J. L.; Jones, S. B.; Liston, D. R.; Nagel, A. A.; Nason, D. M.; Nielsen, J. A.; Shalaby, I. A.; White, W. F. Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase. J. Med. Chem. 1994, 37, 2721-2734.
29. Villalobos, A.; Butler, T. W.; Chapin, D. S.; Chen, Y. L.; Demattos, S. B.; Ives, J. L.; Jones, S. B.; Liston, D. R.; Nagel, A. A.; Nason, D. M.; Nielsen, J. A.; Ramirez, A. D.; Shalaby, I. A.; White, W. F. 5,7-Dihydro-3-[2-[1[(phenylmehtyl)-4-piperidinyl]-ethyl]-6H-pyrrolo[3,2-f]-1, 2-benzisoxazol-6-one: A Potent and Centrally-Selective Inhibitor of Acetylcholinesterase with an Improved Margin of Safety. J. Med. Chem. 1995, 38, 2802-2808.
30. Clark, J. K.; Cowley, P.; Muir, A. W.; Palin, R.; Pow, E.; Prosser, A. B.; Taylor, R.; Zhang, M.-Q. Quaternary Salts of E2020 Analogues as Acetylchoinesterase Inhibitors fo rthe Reversal of Neuromuscular Block. Bioorg. Med. Chem. Lett. 2002, 12, 2565-2568.
31. Eldridge, M. D.; Murray, C. W.; Auton, R. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
32. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
33. Gohlke, H.; Hendlich, M.; Klebe, G. Predicting Binding Modes, Binding Affinities and "Hot Spots" for Protein-Ligand Complexes Using a Knowledge-Based Scoring Function. Perspect. Drug Discovery Des. 2000, 20, 115-144.
34. Wang, T.; Wade, R. C. Comparative binding energy (COMBINE) analysis of OppA-peptide complexes to relate structure to binding thermodynamics. J. Med. Chem. 2002, 45 (22), 4828-4837.
35. Kmunicek, J.; Bohac, M.; Luengo, S.; Gago, F.; Wade, R. C.; Damborsky, J. Comparative binding energy analysis of halo-alkane dehalogenase substrates: modelling of enzyme-substrate complexes by modelcular docking and quantum mechanical calculations. J. Comput.-Aided Mol. Des. 2003, 17 (5-6), 299-311.
36. Murcia, M.; Ortiz, A. R. Virtual screening with flexible docking and COMBINE-based models. Appliction to a series of factor Xa inhibitors. J. Med. Chem. 2004, 47 (4), 805-820.
37. SIMCA-P; Umereics AB, Umea, Sweden, 2001.
38. Shafferman, A.; Velan, B.; Ordentlich, A.; Kronman, C.; Grosfeld, H.; Leitner, M.; Flashner, Y.; Cohen, S.; Barak, D.; Ariel, N. Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from teh surface to the catalytic center. EMBO J. 1992, 11, 3561-3568.
39. Johnson, J. L.; Cusack, B.; Hughes, T. F.; Mccullough, E. H.; Fauq, A.; Romanovskis, P. R.; Spatola, A. F.; Rosenberry, T. L. Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites. J. Biol. Chem. 2003, 278, 38948-38955.
40. Ordentlich, A.; Barak, D.; Kronman, C.; Ariel, N.; Segall, Y.; Valan, B.; Shafferman, A. The architecture of human acetylcholin-esterase active center probed by interactions with selected organophosphate inhibitors. J. Biol. Chem. 1996, 271, 11953-11962.
41. Cramer, R. D., III; Petterson, D. E.; Flume, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.